Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals only.
      BOTOX® (botulinum toxin type A) Prescribing Information and adverse event reporting information can be found below.

      PSS D
      PSS M

      UK-BNO-250045. DOP: May 2025.

      Trust BOTOX® for your patients with post-stroke spasticity (PSS)

      UPPER LIMB & LOWER LIMB:

      BOTOX® has proven evidence and experience in post stroke spasticity in both the upper & lower limb in a range of muscles5-7

      PROVEN EFFICACY: 

      For these patients, BOTOX® showed reduced muscle tone, reduced pain and greater functional goal achievement compared to baseline6-8 

      PROVEN TOLERABILITY: 

      BOTOX® has safety and tolerability experience from +30 years of use in a range of conditions1,5,9,10

      Early identification should affect course of intervention in PSS, which will be key for patients' outcomes.11

      Importance of early identification 

      arrows 1

      Spasticity can cause complications such as impaired movement, difficulty maintaining hygiene and self-care, poor self-esteem and body image, pain and pressure ulcers12

      arrows 2

      Early identification and intervention may help reduce complications and improve outcomes for patients with spasticity12–15

      arrows 3

      Potential barriers to early identification include:16

      • Lack of access to rehabilitation centres
      • Lack of knowledge around spasticity and it’s management
      • Lack of highly qualified or experienced staff and specialists in spasticity or injection

      PSS: post-stroke spasticity.

      EFFICACY DATA FOR BOTOX®

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora SK, et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358–73
      3. Blumenfeld AM, et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Brashear A, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 347:395–400
      7. Kaji R, et al. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol 2010;257(8):1330–37
      8. Gordon MF, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004 ;63(10):1971–73
      9. Allergan. Data on file. INT/0572/2016(2). 2019
      10. Naumann M, et al. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006;13 Suppl 4:35–40
      11. Wissel J, et al. Post-stroke spasticity: predictors of early development and considerations for therapeutic intervention. PM R 2015;7(1):60–67
      12. Royal College of Physicians. Spasticity in adults: management using botulinum toxin. National guidelines 2018. Available at: https://www.rcp.ac.uk/improving-care/resources/spasticity-in-adults-management-using-botulinum-toxin. Accessed June 2025
      13. Graham LA.  Management of spasticity revisited. Age Ageing 2013;42:435–41
      14. Wissel J et al. Toward an epidemiology of post-stoke spasticity. Neurology 2013;80:S13–19
      15. Kuo C-L and Hu G-C. Post-stroke spasticity: A review of epidemiology, pathophysiology, and treatments. Int J Gerontol. 2018;12:280–84
      16. Bowers D et al. Spastic paresis and rehabilitation – The patient journey. Eur Neurol Rev. 2016;11:87–95

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora SK, et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358–73
      3. Blumenfeld AM, et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Brashear A, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 347:395–400
      7. Kaji R, et al. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol 2010;257(8):1330–37
      8. Gordon MF, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004 ;63(10):1971–73
      9. Allergan. Data on file. INT/0572/2016(2). 2019
      10. Naumann M, et al. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006;13 Suppl 4:35–40
      11. Wissel J, et al. Post-stroke spasticity: predictors of early development and considerations for therapeutic intervention. PM R 2015;7(1):60–67
      12. Royal College of Physicians. Spasticity in adults: management using botulinum toxin. National guidelines 2018. Available at: https://www.rcp.ac.uk/improving-care /resources/spasticity-in-adults-management-using-botulinum-toxin. Accessed June 2025
      13. Graham LA.  Management of spasticity revisited. Age Ageing 2013;42:435–41
      14. Wissel J et al. Toward an epidemiology of post-stoke spasticity. Neurology 2013;80:S13–19
      15. Kuo C-L and Hu G-C. Post-stroke spasticity: A review of epidemiology, pathophysiology, and treatments. Int J Gerontol. 2018;12:280–84
      16. Bowers D et al. Spastic paresis and rehabilitation – The patient journey. Eur Neurol Rev. 2016;11:87–95

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here

      BOTOX® PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      Date of preparation: June 2025. UK-BTX-250064.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250217. Date of preparation June 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.